A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 51, 2011, Pages 20695-20700

  Phoolcharoen, Waranyoo ^a,b   Dye, John M ^c   Kilbourne, Jacquelyn ^a   Piensook, Khanrat ^a   Pratt, William D ^c   Arntzen, Charles J ^a,b   Chen, Qiang ^d   Mason, Hugh S ^a,b   Herbst Kralovetz, Melissa M ^a,e  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody antigen fusion; Ebola glycoprotein; Ebola vaccine; Immunopotentiator; Protective antibody

Indexed keywords

EBOLA VACCINE; EPITOPE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EFFECTOR CELL; FEMALE; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; SURVIVAL; VACCINATION;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNOGLOBULIN G; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; POLY I-C; TOLL-LIKE RECEPTOR 3; VACCINES, SUBUNIT;

ANIMALIA; EBOLA VIRUS; MUS;

EID: 84855483647     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117715108     Document Type: Article

References (32)

1. Feldmann H, Klenk HD (1996) Marburg and Ebola viruses. Adv Virus Res 47:1-52.
2. Jaax N, et al. (1995) Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 346:1669-1671. (Pubitemid 26003325)
3. Baize S, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5:423-426. (Pubitemid 29180581)
4. Warfield KL, et al. (2005) Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 175:1184-1191. (Pubitemid 41095006)
5. Wilson JA, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664-1666. (Pubitemid 30127770)
6. Jones TD, Crompton LJ, Carr FJ, Baker MP (2009) Deimmunization of monoclonal antibodies. Methods Mol Biol 525:405-423, xiv.
7. Huang Z, et al. (2010) High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system. Biotechnol Bioeng 106:9-17.
8. Zeitlin L, et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA 108:20690-20694.
9. Falzarano D, Geisbert TW, Feldmann H (2011) Progress in filovirus vaccine development: Evaluating the potential for clinical use. Expert Rev Vaccines 10:63-77.
10. Geisbert TW, Bausch DG, Feldmann H (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20:344-357.
11. Geisbert TW, et al. (2009) Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 83:7296-7304.
12. Pratt WD, et al. (2010) Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 17:572-581.
13. Swenson DL, et al. (2008) Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 15:460-467. (Pubitemid 351967082)
14. Phoolcharoen W, et al. (2011) Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnol J 9:807-816.
15. Pushko P, et al. (2000) Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142-153. (Pubitemid 30618964)
16. Stevens TL, et al. (1988) Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 334:255-258.
17. de Jong JM, et al. (2006) Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo. Mol Immunol 43:2045-2050.
18. Chargelegue D, et al. (2005) Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Infect Immun 73:5915-5922. (Pubitemid 41193029)
19. Marusić M, Marusić-Galesić S, Pokrić B (1992) Humoral immune response to the antigen administered as an immune complex. Immunol Invest 21:623-628.
20. Marusić-Galesić S, Marusić M, Pokrić B (1992) Cellular immune response to the antigen administered as an immune complex in vivo. Immunology 75:325-329.
21. Ichinohe T, et al. (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79:2910-2919. (Pubitemid 40270569)
22. Ashkar AA, et al. (2004) Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 190:1841-1849. (Pubitemid 39487831)
23. Du J, et al. (2010) TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity. Vaccine 28:6273-6281.
24. Cui Z, Qiu F (2006) Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: Therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol Immunother 55:1267-1279. (Pubitemid 43992052)
25. Prins RM, et al. (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity. J Immunol 176:157-164. (Pubitemid 43023259)
26. Boo KH, Yang JS (2010) Intrinsic cellular defenses against virus infection by antiviral type I interferon. Yonsei Med J 51:9-17.
27. Geisbert TW, et al. (2002) Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 8:503-507. (Pubitemid 34533328)
28. Brewer JM (2006) (How) do aluminium adjuvants work? Immunol Lett 102:10-15.
29. Geyer BC, et al. (2010) Transgenic plants as a source for the bioscavenging enzyme, human butyrylcholinesterase. Plant Biotechnol J 8:873-886.
30. Huang Z, Chen Q, Hjelm B, Arntzen C, Mason H (2009) A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnol Bioeng 103:706-714.
31. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178:651-661. (Pubitemid 28397211)
32. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A (1997) Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239:206-216. (Pubitemid 28027084)